Last update 09 Jul 2025

Genakumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Firsekibart, Kinnazumab, 金纳单抗
+ [3]
Target
Action
inhibitors
Mechanism
IL-1β inhibitors(Interleukin-1 beta inhibitors)
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (30 Jun 2025),
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Arthritis, Gouty
China
30 Jun 2025
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Systemic onset juvenile chronic arthritisPhase 3
China
12 Jan 2024
EndometriosisPhase 2
China
16 May 2025
Interstitial lung disease due to connective tissue diseasePhase 2
China
30 Dec 2023
Interstitial lung disease due to systemic diseasePhase 2
China
30 Dec 2023
Rheumatoid arthritis with rheumatoid lung diseasePhase 2
China
30 Dec 2023
Primary goutPhase 2
China
21 Jul 2023
Advanced Malignant Solid NeoplasmPhase 1
China
07 Jun 2022
Polyarticular Juvenile Idiopathic ArthritisClinical
China
01 Dec 2023
Still's Disease, Adult-OnsetIND Approval
United States
14 Jun 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
162
genakumab 100mg
ajurbgncjv(ieyuiapzjc) = vsukcitzfi nuhvifeuns (beycobjtcx )
Positive
11 Jun 2025
genakumab 200mg
ajurbgncjv(ieyuiapzjc) = szrdoqhdrq nuhvifeuns (beycobjtcx )
Phase 2
Primary gout
First line
123
pneksliwvd(eqfpekxcnz) = wivjfxccyn fksginoizu (acexgnmiek )
Met
Positive
11 Jun 2025
etoricoxib
pneksliwvd(eqfpekxcnz) = vnpptvhuki fksginoizu (acexgnmiek )
Met
Phase 3
313
zwbhoacprx(zkqchzaaur) = dhhakriwpk ldxdmyaedg (cornpjvmco, -60.08 to -54.10)
Met
Positive
11 Jun 2025
Compound Betamethasone
zwbhoacprx(zkqchzaaur) = jgdxepycdd ldxdmyaedg (cornpjvmco, -56.77 to -50.77)
Met
Phase 3
313
gigbpjjzbq(nkvlxjxhbe): Difference (Mean) = -3.32 (95% CI, -7.56 to 0.91)
Positive
16 Nov 2024
Compound betamethasone
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free